




Applicant:	Wayne P. Franco.	37 C.F.R. § 1.8 Certificate of Mailing I hereby certify that this correspondence is today being deposited with the U.S. Postal Service in an envelope with appropriate postage affixed thereto and addressed to Commissioner for Patents and Trademarks, Washington, D.C. 20231. January 21, 2003  Daniel F. Coughlin
Serial No.:	09/828,330	
Filing Date:	6 April 2001	
Group Art Unit	1647	
Examiner	Christine J. Saoud	
Title of Application:	Methods of Use of Fibroblast Growth Factor, Vascular Endothelial Growth Factor and Related Proteins in the Treatment of Acute and Chronic Heart Disease	

January 21, 2003


Commissioner For Patents
Washington, DC 20231

Transmittal Letter

Sir:

Transmitted herewith is the Response to the Office Action of September 18, 2003, Petition for Extension of Time; check for \$55; Declaration of Wayne P. Franco; Copies of Transmittal of Sequence Listing; Sequence Listing; Notice to Supply Sequence Listing; Missing pages 40,45, 50, 57, and 65; and WO 01/77328.

Respectfully submitted,



Daniel F. Coughlin, Reg. No. 36,111
Cummings & Lockwood
700 State Street
New Haven, CT 06509-1960
Tele: (203) 351-4622

RECEIVED
JAN 30 2003
TECH CENTER 1600/2900

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Application No.: 09/828,330

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: The specification must make reference to the relevant sequence identifier (i.e., SEQ ID NO:) at each disclosure of a sequence embraced by the definitions set forth in 37 CFR 1.821-1.825.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". Alternatively, Applicant may request transfer of the CRF listing from the parent application if it is the same as that in the instant application. Please see attached Sample Request.
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. Applicant must provide this even if they choose to request transfer of the CRF.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE